Clinical observation of candesartan in treatment of elderly primary hypertension and its complications

Objective To investigate the clinical effect of candesartan in treatment of elderly primary hypertension and its complications. Methods The patients with primary hypertension(150 cases) of General Hospital of Hebei Central Energy Fengfeng Group Co., LTD from January 2011 to January 2014 were randomly divided into control and treatment groups, and each group had 75 cases. The patients in the control group were given conventional therapy. The patients in the treatment group were po administered with Candesartan Cilexetil Tablets at the basis of control group, 1 tablet/time, once daily. The patients in two groups were treated for 24 weeks. After treatment, the efficacy was evaluated, while the changes of LVDd, LVPWT, VST, and IMT were detected. Results The efficacies in the control and treatment groups were 81.33% and 96.00%, respectively, and there were differences between the two groups(P 0.05). After treatment, systolic blood pressure and diastolic blood pressure in two groups significantly decreased, and the difference was statistically significant in the same group before and after treatment(P 0.05). Systolic blood pressure and diastolic blood pressure in treatment group decreased more than those in the control group, and there were differences between two groups(P 0.05). After treatment, LVDd, LVPWT, VST, and IMT in treatment group significantly decreased, and the difference was statistically significant in the same group before and after treatment(P 0.05). But there was no difference before and after treatment about these indexes in the control group. After treatment, the values of LVDd, LVPWT, VST, and IMT in the treatment group were lower than those in the control group, and there were differences between two groups(P 0.05). Conclusion Candesartan has the good clinical effect in treatment of elderly primary hypertension and its complications, and can significantly decrease the blood pressure and improve the condition of atherosclerosis and left ventricular hypertrophy, which is worth clinical promotion.